Mayzent and Weight decreased - a phase IV clinical study of FDA data

Summary:

Weight decreased is reported as a side effect among people who take Mayzent (siponimod fumaric acid), especially for people who are female, 50-59 old, have been taking the drug for 6 - 12 months also take Gilenya, and have Multiple sclerosis.

The phase IV clinical study analyzes which people have Weight decreased when taking Mayzent. It is created by eHealthMe based on reports of 10,267 people who have side effects when taking Mayzent from the FDA, and is updated regularly.

What is Mayzent?

Mayzent has active ingredients of siponimod fumaric acid. eHealthMe is studying from 10,269 Mayzent users. Check the latest studies of Mayzent.

What is Weight decreased?

Weight decreased is found to be associated with 3,391 drugs and 4,748 conditions by eHealthMe. Check the latest studies of Weight decreased.

On Jul, 21, 2026

10,267 people reported to have side effects when taking Mayzent.
Among them, 95 people (0.93%) have Weight decreased.

Among these 95 people:

How long have people been on Mayzent when they have Weight decreased? *

What is the gender of people who have Weight decreased when taking Mayzent? *

female: 84.04 %
male: 15.96 %

What is the age of people who have Weight decreased when taking Mayzent? *

What are other drugs people take besides Mayzent? *

What are other side effects people have besides Weight decreased? *

Fatigue (feeling of tiredness): 26 people, 27.37%
Weakness: 26 people, 27.37%
Nausea (feeling of having an urge to vomit): 21 people, 22.11%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 15 people, 15.79%
Hypoaesthesia (reduced sense of touch or sensation): 14 people, 14.74%
Headache (pain in head): 14 people, 14.74%
Stress And Anxiety: 13 people, 13.68%
Fall: 12 people, 12.63%
Memory Loss: 12 people, 12.63%
Pain In Extremity: 12 people, 12.63%

What are the existing conditions these people have? *

Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 48 people, 50.53%
Secondary Progressive Multiple Sclerosis (a stage of ms which comes after relapsing remitting ms in many cases): 28 people, 29.47%
Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 6 people, 6.32%
Primary Progressive Multiple Sclerosis (primary progressive inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 5 people, 5.26%
Clinically Isolated Syndrome (individual's first neurological episode, caused by inflammation or demyelination of nerve tissue): 5 people, 5.26%
High Blood Pressure: 4 people, 4.21%
Multiple Sclerosis Relapse (reoccurrence of a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 3 people, 3.16%
Type 2 Diabetes: 2 people, 2.11%
Progressive Relapsing Multiple Sclerosis (chronic autoimmune disease of the central nervous system in which gradual destruction of myelin occurs in patches throughout the brain or spinal cord or both): 2 people, 2.11%
Hyperthyroidism (over activity of the thyroid gland): 2 people, 2.11%

* Approximation only. Some reports may have incomplete information.

Do you take Mayzent and have Weight decreased?

- Check whether Weight decreased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Mayzent:

Mayzent (10,269 reports)

Weight decreased treatments and more:

Weight decreased (364,522 reports)

Browse all side effects of Mayzent:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Weight decreased:

Weight decreased (3,391 drugs)

Browse all the conditions that are associated with Weight decreased:

Weight decreased (4,748 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on siponimod fumaric acid (the active ingredients of Mayzent) and Mayzent (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.